Internet Enduring Material sponsored and presented by the Center for Continuing Medical Education at the Stanford School of Medicine. This is a recorded presentation of the Prostate Cancer CME Series: Treatment Across the Prostate Cancer Continuum for Primary Care Clinicians held on Monday, March 21, 2022. The goal of the series is to enhance understanding of increasingly complex treatment options and close knowledge gaps in earlier stages of prostate cancer. This session was targeted towards the primary care clinicians and included a discussion on the historical landscape of testing, blood based diagnostic biomarkers and screening, the latest in diagnostics, role of genetics and genomics and highlight existing disparities in prostate cancer.
Sign in to take quiz and track your certificates
To help improve the quality of its educational content and meet applicable education accreditation requirements, the content provider will receive record of your participation and responses to this activity.
Stanford Medicine offers CME on a variety of topics that is evidence-based, references best practices supported by scientific literature and guidelines and is free of commercial bias. Learn more
All Rights Reserved. The content of this activity is protected by U.S. and International copyright laws. Reproduction and distribution of its content without written permission of its creator(s) is prohibited.
This CME activity is supported by an educational grant from Astellas Pharma Global Development, Inc. and its collaborative partner, Pfizer, Inc.
Financial Support Disclosure Statement: Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.
There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the below table. All of the relevant financial relationships listed for these individuals have been mitigated.
Ali R Khaki, MD
Clinical Assistant Professor
Stanford Health Care (SHC)
Co-Course Director, Faculty
Stocks or stock options, excluding diversified mutual funds-Merck and Company, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Sanofi-Aventis (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Doximity (Relationship has ended)
Hala Borno, MD
Assistant Professor, Medicine
Paid consultant-AstraZeneca (Relationship has ended)|Executive-Trial Libray, Inc
Matthew R Cooperberg, MD, MPH
Professor of Urology; Epidemiology & Biostatistics
Consulting Fee-Dendreon|Consulting Fee-AstraZeneca|Consulting Fee-Astellas|Consulting Fee-Veracyte|Consulting Fee-Verana|Consulting Fee-Exact Sciences|Consulting Fee-Pfizer, Inc. (Relationship has ended)|Consulting Fee-Bayer Corporation (Relationship has ended)|Consulting Fee-Merck and Company, Inc. (Relationship has ended)|Consulting Fee-Exelixis (Relationship has ended)|Consulting Fee-Foundation Medicine (Relationship has ended)
John Leppert, MD, MS
Nothing to disclose
Sumit Anil Shah, MD
Advisor-Natera|Grant or research support-Genentech, Inc.
Geoffrey Alexander Sonn, MD
Assistant Professor of Urology
Ruth Adewuya, MD, CHCP
Managing Director, CME
Stanford University School of Medicine
Laura Ruffo, NP
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Stanford Medicine designates this Enduring Material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Statement: Upon completion of this activity, learners will receive a Participation Certificate.
You currently have no searches saved.
You currently have no courses saved.